Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 70.95 Million SEK | -40.31% |
| 2022 | 116.04 Million SEK | 528.88% |
| 2021 | 18.45 Million SEK | 261.75% |
| 2020 | 5.1 Million SEK | 104.2% |
| 2019 | 2.49 Million SEK | 2.29% |
| 2018 | 2.44 Million SEK | -24.19% |
| 2017 | 3.22 Million SEK | 36.37% |
| 2016 | 2.36 Million SEK | -50.54% |
| 2015 | 4.77 Million SEK | 6.82% |
| 2014 | 4.47 Million SEK | 217.31% |
| 2013 | 1.4 Million SEK | -72.4% |
| 2012 | 5.1 Million SEK | 1280.67% |
| 2011 | -432.43 Thousand SEK | -109.72% |
| 2010 | 4.44 Million SEK | 49.08% |
| 2009 | 2.98 Million SEK | 2777.99% |
| 2008 | 103.67 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -6.19 Million SEK | -116.38% |
| 2024 Q3 | 37.28 Million SEK | 701.94% |
| 2024 Q1 | 37.82 Million SEK | 17.15% |
| 2023 Q1 | 14.54 Million SEK | -44.54% |
| 2023 Q3 | 6.18 Million SEK | -65.54% |
| 2023 FY | 69.26 Million SEK | -40.31% |
| 2023 Q4 | 32.28 Million SEK | 422.33% |
| 2023 Q2 | 17.93 Million SEK | 23.3% |
| 2022 Q2 | 21.32 Million SEK | 11.94% |
| 2022 Q1 | 19.04 Million SEK | 61.75% |
| 2022 FY | 116.04 Million SEK | 528.88% |
| 2022 Q4 | 26.23 Million SEK | -46.95% |
| 2022 Q3 | 49.45 Million SEK | 131.93% |
| 2021 Q2 | 2.2 Million SEK | -69.69% |
| 2021 Q1 | 7.26 Million SEK | 98.74% |
| 2021 FY | 18.45 Million SEK | 261.75% |
| 2021 Q3 | -2.78 Million SEK | -226.61% |
| 2021 Q4 | 11.77 Million SEK | 522.35% |
| 2020 FY | 5.1 Million SEK | 104.2% |
| 2020 Q1 | 462 Thousand SEK | -55.7% |
| 2020 Q2 | 507 Thousand SEK | 9.74% |
| 2020 Q3 | 477 Thousand SEK | -5.92% |
| 2020 Q4 | 3.65 Million SEK | 666.25% |
| 2019 Q4 | 1.04 Million SEK | 134.91% |
| 2019 Q3 | 444 Thousand SEK | -10.3% |
| 2019 Q2 | 495 Thousand SEK | -4.07% |
| 2019 Q1 | 516 Thousand SEK | -16.91% |
| 2019 FY | 2.49 Million SEK | 2.29% |
| 2018 FY | 2.44 Million SEK | -24.19% |
| 2018 Q1 | 538 Thousand SEK | -43.96% |
| 2018 Q4 | 621 Thousand SEK | 43.09% |
| 2018 Q3 | 434 Thousand SEK | -48.88% |
| 2018 Q2 | 849 Thousand SEK | 57.81% |
| 2017 Q3 | 624 Thousand SEK | -2.5% |
| 2017 Q4 | 960 Thousand SEK | 53.85% |
| 2017 FY | 3.22 Million SEK | 36.37% |
| 2017 Q1 | 997 Thousand SEK | 11.02% |
| 2017 Q2 | 640 Thousand SEK | -35.81% |
| 2016 Q1 | 488 Thousand SEK | 478.29% |
| 2016 FY | 2.36 Million SEK | -50.54% |
| 2016 Q3 | 488 Thousand SEK | 0.0% |
| 2016 Q4 | 898 Thousand SEK | 84.02% |
| 2016 Q2 | 488 Thousand SEK | 0.0% |
| 2015 FY | 4.77 Million SEK | 6.82% |
| 2015 Q1 | 3.84 Million SEK | 18.19% |
| 2015 Q3 | 529 Thousand SEK | 0.0% |
| 2015 Q2 | 529 Thousand SEK | -86.25% |
| 2015 Q4 | -129 Thousand SEK | -124.39% |
| 2014 Q3 | - SEK | -100.0% |
| 2014 Q4 | 3.25 Million SEK | 0.0% |
| 2014 Q1 | 1.45 Million SEK | 198.14% |
| 2014 Q2 | 349 Thousand SEK | -76.05% |
| 2014 FY | 4.47 Million SEK | 217.31% |
| 2013 Q3 | -1.48 Million SEK | 21.64% |
| 2013 Q2 | -1.89 Million SEK | -0.0% |
| 2013 Q4 | -1.48 Million SEK | 0.0% |
| 2013 Q1 | -1.89 Million SEK | 35.5% |
| 2013 FY | 1.4 Million SEK | -72.4% |
| 2012 Q4 | -2.93 Million SEK | 0.0% |
| 2012 FY | 5.1 Million SEK | 1280.67% |
| 2011 FY | -432.43 Thousand SEK | -109.72% |
| 2010 FY | 4.44 Million SEK | 49.08% |
| 2009 FY | 2.98 Million SEK | 2777.99% |
| 2008 FY | 103.67 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 144.155% |
| Ziccum AB (publ) | -23.28 Million SEK | 404.694% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 79.513% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | -69.792% |
| Mendus AB (publ) | 28.48 Million SEK | -149.064% |
| Genovis AB (publ.) | 54 Million SEK | -31.388% |
| Intervacc AB (publ) | -13.79 Million SEK | 614.361% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -3168.125% |
| Active Biotech AB (publ) | -1.67 Million SEK | 4335.881% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -612.145% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -164.535% |
| Aptahem AB (publ) | 2.63 Million SEK | -2597.092% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 2173.984% |
| Kancera AB (publ) | -1.96 Million SEK | 3710.738% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -92044.156% |
| Fluicell AB (publ) | 1.73 Million SEK | -3982.336% |
| Saniona AB (publ) | 11.78 Million SEK | -502.249% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 1486.574% |
| Biovica International AB (publ) | 6.87 Million SEK | -931.714% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 404.733% |
| AcouSort AB (publ) | 8.38 Million SEK | -745.762% |
| Xintela AB (publ) | 78 Thousand SEK | -90862.821% |
| Abliva AB (publ) | -35.66 Million SEK | 298.948% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 148.299% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -2427.645% |
| OncoZenge AB (publ) | 3000.00 SEK | -2364933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 3776.218% |
| 2cureX AB (publ) | -37.48 Million SEK | 289.268% |
| CombiGene AB (publ) | -21.29 Million SEK | 433.249% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 16873.286% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 93.72% |
| Camurus AB (publ) | 1.58 Billion SEK | 95.511% |
| Corline Biomedical AB | 28.38 Million SEK | -150.004% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 157.809% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 306.163% |
| I-Tech AB | 27.56 Million SEK | -157.386% |
| Cyxone AB (publ) | 2.61 Million SEK | -2617.388% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -1984.954% |
| Biosergen AB | -456 Thousand SEK | 15659.43% |
| Cantargia AB (publ) | -3.45 Million SEK | 2155.955% |
| NextCell Pharma AB | -43.74 Million SEK | 262.181% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 871.71% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -532.458% |
| Nanologica AB (publ) | -76 Thousand SEK | 93456.579% |
| SynAct Pharma AB | -778 Thousand SEK | 9219.666% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 36862.176% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 649.071% |
| Lipum AB (publ) | 53 Thousand SEK | -133769.811% |
| BioInvent International AB (publ) | 71.46 Million SEK | 0.714% |
| Alzinova AB (publ) | 19.87 Million SEK | -257.004% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -95.463% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -4749.626% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 473106.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -4179.312% |
| Simris Alg AB (publ) | 2 Million SEK | -3435.177% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 2081.872% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -100.495% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 6863.68% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -2164.635% |